Atalanta Therapeutics Secures $97 Million to Advance siRNA Therapies for Neurological Disorders

January 30, 2025

Amgen’s Drug for Small Cell Lung Cancer Receives US FDA Approval

May 20, 2024

Can AI Streamline FDA Regulatory Submissions in Life Sciences?

April 1, 2026

Must Read

Ionis and AstraZeneca falter as the ATTR-CM medication fails Phase 3

July 19, 2026

Merck Makes History By Getting FDA Green Light For Lipfendra

July 19, 2026

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

July 19, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Early research shows that Lilly’s Verve strategy is successful in lowering cholesterol

Kailera Details Nasdaq IPO Plans to Raise Up to $528.5 Million for Obesity Drug Development

Ionis and AstraZeneca falter as the ATTR-CM medication fails Phase 3

Axiom Reports Phase 1 Results for Stem Cell Therapy in Newborn Brain Injuries

Sac-TMT and Keytruda Improve Progression-Free Survival in PD-L1-Negative NSCLC

Veradermics Reports Phase 2 Results for VDPHL01 in Women With Pattern Hair Loss

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

AstraZeneca travels to China once more and purchases Dizal’s lung cancer medication for up to $1.5 billion

Spero Shells Out Over $1B For Innovent’s Autoimmune Antibody

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

Wisp Launches Weight Care Vertical for Women with Hormonal Imbalances

The Future of Smart Biopharmaceutical Manufacturing

Top 10 Risks Pharma Leaders Underestimate in AI Deployment

Top 10 Barriers to Scaling Genomics Programs in Healthcare

The Rise of AI-Native Biotech Companies

Regulatory

Phase 3 Approval of Novartis’ BTK Inhibitor Raises Concerns about Dupixent’s Risks

Editor Picks

Atalanta Therapeutics Secures $97 Million to Advance siRNA Therapies for Neurological Disorders

Amgen’s Drug for Small Cell Lung Cancer Receives US FDA Approval

Can AI Streamline FDA Regulatory Submissions in Life Sciences?

Must Read

Ionis and AstraZeneca falter as the ATTR-CM medication fails Phase 3

Merck Makes History By Getting FDA Green Light For Lipfendra

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

Hot Topics

About Us

Follow Us